Compare CULP & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CULP | COCH |
|---|---|---|
| Founded | 1972 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Textiles | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 50.6M |
| IPO Year | 1994 | N/A |
| Metric | CULP | COCH |
|---|---|---|
| Price | $3.07 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 37.4K | ★ 116.1K |
| Earning Date | 03-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $213,237,000.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.70 | $0.36 |
| 52 Week High | $4.75 | $1.89 |
| Indicator | CULP | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 44.38 |
| Support Level | $2.71 | $0.63 |
| Resistance Level | $3.13 | $0.73 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 7.58 | 23.55 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.